platinum has been researched along with bmn 673 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Balmaña, J; Chappey, C; Ettl, J; Fasching, PA; Grischke, EM; Hannah, AL; Hurvitz, SA; Mailliez, A; Mina, LA; Robson, ME; Rugo, HS; Telli, ML; Turner, NC; Wardley, AM | 1 |
| Bonnet, I; Boutrois, J; Brachet, PE; Castera, M; Clarisse, B; Coquan, E; Goardon, N; Grellard, JM; Joly, F; Lequesne, J; Meriaux, E; Nevière, Z; Thiery-Vuillemin, A; Travers, R | 1 |
2 trial(s) available for platinum and bmn 673
| Article | Year |
|---|---|
A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Cohort Studies; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Germ-Line Mutation; Humans; Middle Aged; Neoplasm Metastasis; Phthalazines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Prognosis; Salvage Therapy | 2019 |
TALASUR trial: a single arm phase II trial assessing efficacy and safety of TALazoparib and Avelumab as maintenance therapy in platinum-Sensitive metastatic or locally advanced URothelial carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Female; Humans; Male; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Quality of Life; Urinary Bladder Neoplasms | 2022 |